95 related articles for article (PubMed ID: 21641213)
1. Novel purine-based fluoroaryl-1,2,3-triazoles as neuroprotecting agents: synthesis, neuronal cell culture investigations, and CDK5 docking studies.
Nair N; Kudo W; Smith MA; Abrol R; Goddard WA; Reddy VP
Bioorg Med Chem Lett; 2011 Jul; 21(13):3957-61. PubMed ID: 21641213
[TBL] [Abstract][Full Text] [Related]
2. Potent inhibitors of CDK5 derived from roscovitine: synthesis, biological evaluation and molecular modelling.
Demange L; Abdellah FN; Lozach O; Ferandin Y; Gresh N; Meijer L; Galons H
Bioorg Med Chem Lett; 2013 Jan; 23(1):125-31. PubMed ID: 23218601
[TBL] [Abstract][Full Text] [Related]
3. Suzuki-type Pd(0) coupling reactions in the synthesis of 2-arylpurines as Cdk inhibitors.
Vandromme L; Piguel S; Lozach O; Meijer L; Legraverend M; Grierson DS
Bioorg Med Chem Lett; 2006 Jun; 16(12):3144-6. PubMed ID: 16616489
[TBL] [Abstract][Full Text] [Related]
4. Potential neuroprotective flavonoid-based inhibitors of CDK5/p25 from Rhus parviflora.
Shrestha S; Natarajan S; Park JH; Lee DY; Cho JG; Kim GS; Jeon YJ; Yeon SW; Yang DC; Baek NI
Bioorg Med Chem Lett; 2013 Sep; 23(18):5150-4. PubMed ID: 23927974
[TBL] [Abstract][Full Text] [Related]
5. Different mechanisms of CDK5 and CDK2 activation as revealed by CDK5/p25 and CDK2/cyclin A dynamics.
Otyepka M; Bártová I; Kríz Z; Koca J
J Biol Chem; 2006 Mar; 281(11):7271-81. PubMed ID: 16407256
[TBL] [Abstract][Full Text] [Related]
6. Advances in tetrahydropyrido[1,2-a]isoindolone (valmerins) series: Potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors.
Boulahjar R; Ouach A; Bourg S; Bonnet P; Lozach O; Meijer L; Guguen-Guillouzo C; Le Guevel R; Lazar S; Akssira M; Troin Y; Guillaumet G; Routier S
Eur J Med Chem; 2015 Aug; 101():274-87. PubMed ID: 26142492
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of aberrant cyclin-dependent kinase 5 activity attenuates isoflurane neurotoxicity in the developing brain.
Wang WY; Luo Y; Jia LJ; Hu SF; Lou XK; Shen SL; Lu H; Zhang HH; Yang R; Wang H; Ma ZW; Xue QS; Yu BW
Neuropharmacology; 2014 Feb; 77():90-9. PubMed ID: 24055498
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of 1,4-disubstituted 1,2,3-triazole Derivatives Using Click Chemistry and their Src Kinase Activities.
Lebeau A; Abrioux C; Bénimèlis D; Benfodda Z; Meffre P
Med Chem; 2016; 13(1):40-48. PubMed ID: 27041552
[TBL] [Abstract][Full Text] [Related]
9. A Pd(0) based cross-coupling approach to the synthesis of 2-amidopurines and their evaluation as CDK inhibitors.
Vandromme L; Legraverend M; Kreimerman S; Lozach O; Meijer L; Grierson DS
Bioorg Med Chem; 2007 Jan; 15(1):130-41. PubMed ID: 17064911
[TBL] [Abstract][Full Text] [Related]
10. 'Click' synthesis of a triazole-based inhibitor of Met functions in cancer cells.
Colombo F; Tintori C; Furlan A; Borrelli S; Christodoulou MS; Dono R; Maina F; Botta M; Amat M; Bosch J; Passarella D
Bioorg Med Chem Lett; 2012 Jul; 22(14):4693-6. PubMed ID: 22738633
[TBL] [Abstract][Full Text] [Related]
11. Binding mechanism of CDK5 with roscovitine derivatives based on molecular dynamics simulations and MM/PBSA methods.
Dong K; Wang X; Yang X; Zhu X
J Mol Graph Model; 2016 Jul; 68():57-67. PubMed ID: 27371933
[TBL] [Abstract][Full Text] [Related]
12. Molecular models of cyclin-dependent kinase 1 complexed with inhibitors.
Canduri F; Uchoa HB; de Azevedo WF
Biochem Biophys Res Commun; 2004 Nov; 324(2):661-6. PubMed ID: 15474478
[TBL] [Abstract][Full Text] [Related]
13. Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models.
Menn B; Bach S; Blevins TL; Campbell M; Meijer L; Timsit S
PLoS One; 2010 Aug; 5(8):e12117. PubMed ID: 20711428
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders.
Wrasidlo W; Crews LA; Tsigelny IF; Stocking E; Kouznetsova VL; Price D; Paulino A; Gonzales T; Overk CR; Patrick C; Rockenstein E; Masliah E
Br J Pharmacol; 2014 Dec; 171(24):5757-73. PubMed ID: 25117211
[TBL] [Abstract][Full Text] [Related]
15. The role of CDK5/P25 formation/inhibition in neurodegeneration.
Camins A; Verdaguer E; Folch J; Canudas AM; Pallàs M
Drug News Perspect; 2006 Oct; 19(8):453-60. PubMed ID: 17160145
[TBL] [Abstract][Full Text] [Related]
16. Click approach to the discovery of 1,2,3-triazolylsalicylamides as potent Aurora kinase inhibitors.
Song D; Park Y; Yoon J; Aman W; Hah JM; Ryu JS
Bioorg Med Chem; 2014 Sep; 22(17):4855-66. PubMed ID: 25042560
[TBL] [Abstract][Full Text] [Related]
17. Molecular basis of differential selectivity of cyclobutyl-substituted imidazole inhibitors against CDKs: insights for rational drug design.
Rath SL; Senapati S
PLoS One; 2013; 8(9):e73836. PubMed ID: 24058495
[TBL] [Abstract][Full Text] [Related]
18. Ynamide Click chemistry in development of triazole VEGFR2 TK modulators.
Vojtičková M; Dobiaš J; Hanquet G; Addová G; Cetin-Atalay R; Yildirim DC; Boháč A
Eur J Med Chem; 2015 Oct; 103():105-22. PubMed ID: 26344911
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of (glycopyranosyl-triazolyl)-purines and their inhibitory activities against protein tyrosine phosphatase 1B (PTP1B).
Luo L; He XP; Shen Q; Li JY; Shi XX; Xie J; Li J; Chen GR
Chem Biodivers; 2011 Nov; 8(11):2035-44. PubMed ID: 22083916
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of 6-oxo-1,6-dihydropyridines as CDK5 inhibitors.
Kaller MR; Zhong W; Henley C; Magal E; Nguyen T; Powers D; Rzasa RM; Wang W; Xiong X; Norman MH
Bioorg Med Chem Lett; 2009 Dec; 19(23):6591-4. PubMed ID: 19864130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
